CORCEPT THERAPEUTICS INC Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
CORCEPT THERAPEUTICS INC (CORT) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $1.00 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-03.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2020-11-03
- CORCEPT THERAPEUTICS INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for the quarter ending 2020-09-30 was $1.00M, a 100.00% increase year-over-year.
- CORCEPT THERAPEUTICS INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for the quarter ending 2020-06-30 was $1.00M, a 233.33% increase year-over-year.
- CORCEPT THERAPEUTICS INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for the quarter ending 2020-03-31 was $100.00K.
- CORCEPT THERAPEUTICS INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for the quarter ending 2019-09-30 was $500.00K.
- CORCEPT THERAPEUTICS INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2015 was $6.00K, a 99.11% decline from fiscal 2014.
- CORCEPT THERAPEUTICS INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2014 was $673.00K, a 18.69% increase from fiscal 2013.
- CORCEPT THERAPEUTICS INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2013 was $567.00K, a 40.35% increase from fiscal 2012.
- CORCEPT THERAPEUTICS INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2012 was $404.00K, a 44.29% increase from fiscal 2011.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 3 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 6 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 9 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|---|---|---|
| 2020-09-30 | $1.00M 10-Q · filed 2020-11-03 | $2.00M derived: sum of 2 quarters · filed 2020-11-03 | $2.10M 10-Q · filed 2020-11-03 | |
| 2020-06-30 | $1.00M 10-Q · filed 2020-08-04 | $1.10M 10-Q · filed 2020-08-04 | ||
| 2020-03-31 | $100.00K 10-Q · filed 2020-05-04 | |||
| 2019-09-30 | $500.00K 10-Q · filed 2019-11-07 | $800.00K derived: sum of 2 quarters · filed 2019-11-07 | $3.60M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $300.00K 10-Q · filed 2019-08-01 | $3.20M 10-Q · filed 2019-08-01 | ||
| 2019-03-31 | -$2.80M 10-Q · filed 2019-05-09 | |||
| 2015-12-31 | $6.00K 10-K · filed 2016-03-10 | |||
| 2014-12-31 | $673.00K 10-K · filed 2016-03-10 | |||
| 2013-12-31 | $567.00K 10-K · filed 2016-03-10 | |||
| 2012-12-31 | $404.00K 10-K · filed 2015-03-13 | |||
| 2011-12-31 | $280.00K 10-K · filed 2014-03-14 | |||
| 2010-12-31 | $189.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |